New REGEN-COV™ (casirivimab and imdevimab) Data Show Supportive Results in Patients Hospitalized with COVID-19

TARRYTOWN, N.Y. , Sept. 30, 2021 /PRNewswire/ —  Trial met primary endpoint, showing REGEN-COV significantly reduced viral load within 7 days of treatment; trial conducted in patients hospitalized with COVID-19 who did not require high-flow oxygen or mechanical ventilation at baseline Numeric

close

Get every new post delivered right to your inbox.

Original Source